[Click eStock] "KainosMed, a Game Changer in Parkinson's Disease Treatment"

On the 11th, KB Securities analyzed Kainosmed as a game changer for Parkinson's disease treatment.

Kainosmed, an innovative drug development company, has major pipelines including treatments for Parkinson's disease and multiple system atrophy (KM-819), and an AIDS treatment (KM-023). Currently, Parkinson's disease, multiple system atrophy, and AIDS are intractable diseases with no adequate therapeutic drugs. Kainosmed is researching and developing First & Best new drugs aimed at fundamental treatment rather than symptom relief for these intractable diseases, using differentiated substances and technology.

Researcher Lim from KB Securities explained in a report on the same day, "The most notable candidate currently is the Parkinson's disease treatment KM-819, which is attracting growing interest as a potential game changer in the Parkinson's treatment field," adding, "KM-819 is being developed as a therapeutic agent with a dual mechanism of action by inhibiting the protein FAF1, thereby suppressing the death of dopamine-secreting nerve cells and reducing a-synuclein accumulation."

Researcher Lim stated, "So far, there is no drug that fundamentally cures Parkinson's disease; most products only alleviate symptoms," and added, "Currently, after completing Part 1 of Phase 2 clinical trials in the United States, preparations for Part 2 of Phase 2 clinical trials are underway."

He also explained, "The value of the treatment substance for multiple system atrophy (MSA), which is similar to Parkinson's disease, is being highlighted," and noted, "It has been confirmed that KM-819 has a life-extension effect (in animal experiments) by reducing the accumulation of a-synuclein, a causative factor of MSA."

He forecasted, "There is a plan for a new IND for Phase 2 clinical trials in Korea (after voluntarily withdrawing from the ongoing Korean Phase 2 trial), and since it is classified as a treatment for rare diseases, conditional approval is possible if Phase 2 is successful," adding, "Success in Phase 2 for MSA is likely to be used as a predictive basis for the success of KM-819 as a Parkinson's disease treatment."

Furthermore, he analyzed, "The AIDS treatment KM-023, which was successfully licensed out to China, is currently generating royalties (2% of sales in the Chinese market) through the partner company and has been recognized as revenue since 2022," and added, "Significant performance growth is expected upon completion of global clinical trials and regulatory approval in the United States, Europe, and other regions."